References
- Gullo I, Carneiro F, Oliveira C, Almeida GM. Heterogeneity in gastric cancer: from pure morphology to molecular classifications. Pathobiology 2018;85:50-63. https://doi.org/10.1159/000473881
- Schlosser HA, Drebber U, Urbanski A, Haase S, Baltin C, Berlth F, et al. Glucose transporters 1, 3, 6, and 10 are expressed in gastric cancer and glucose transporter 3 is associated with UICC stage and survival. Gastric Cancer 2017;20:83-91. https://doi.org/10.1007/s10120-015-0577-x
- Berlth F, Monig SP, Schlosser HA, Maus M, Baltin CT, Urbanski A, et al. Validation of 2-mm tissue microarray technology in gastric cancer. Agreement of 2-mm TMAs and full sections for GLUT-1 and HIF-1 alpha. Anticancer Res 2014;34:3313-3320.
- Alakus H, Batur M, Schmidt M, Drebber U, Baldus SE, Vallbohmer D, et al. Variable 18F-fluorodeoxyglucose uptake in gastric cancer is associated with different levels of GLUT-1 expression. Nucl Med Commun 2010;31:532-538. https://doi.org/10.1097/mnm.0b013e32833823ac
- Berlth F, Monig S, Pinther B, Grimminger P, Maus M, Schlosser H, et al. Both GLUT-1 and GLUT-14 are independent prognostic factors in gastric adenocarcinoma. Ann Surg Oncol 2015;22 Suppl 3:S822-S831.
- Chon HJ, Kim C, Cho A, Kim YM, Jang SJ, Kim BO, et al. The clinical implications of FDG-PET/CT differ according to histology in advanced gastric cancer. Gastric Cancer 2019;22:113-122. https://doi.org/10.1007/s10120-018-0847-5
-
Findlay JM, Antonowicz S, Segaran A, El Kafsi J, Zhang A, Bradley KM, et al. Routinely staging gastric cancer with
$^{18}F$ -FDG PET-CT detects additional metastases and predicts early recurrence and death after surgery. Eur Radiol 2019;29:2490-2498. https://doi.org/10.1007/s00330-018-5904-2 - Borggreve AS, Goense L, Brenkman HJ, Mook S, Meijer GJ, Wessels FJ, et al. Imaging strategies in the management of gastric cancer: current role and future potential of MRI. Br J Radiol 2019;92:20181044. https://doi.org/10.1259/bjr.20181044
- Brenkman HJ, Gertsen EC, Vegt E, van Hillegersberg R, van Berge Henegouwen MI, Gisbertz SS, et al. Evaluation of PET and laparoscopy in STagIng advanced gastric cancer: a multicenter prospective study (PLASTIC-study). BMC Cancer 2018;18:450. https://doi.org/10.1186/s12885-018-4367-9
- Lai Y, Wei X, Lin S, Qin L, Cheng L, Li P. Current status and perspectives of patient-derived xenograft models in cancer research. J Hematol Oncol 2017;10:106. https://doi.org/10.1186/s13045-017-0470-7
- Choi YY, Lee JE, Kim H, Sim MH, Kim KK, Lee G, et al. Establishment and characterisation of patient-derived xenografts as paraclinical models for gastric cancer. Sci Rep 2016;6:22172. https://doi.org/10.1038/srep22172
- Sulaiman A, Wang L. Bridging the divide: preclinical research discrepancies between triple-negative breast cancer cell lines and patient tumors. Oncotarget 2017;8:113269-113281. https://doi.org/10.18632/oncotarget.22916
-
Fueger BJ, Czernin J, Hildebrandt I, Tran C, Halpern BS, Stout D, et al. Impact of animal handling on the results of
$^{18}F$ -FDG PET studies in mice. J Nucl Med 2006;47:999-1006. - Ko GB, Yoon HS, Kim KY, Lee MS, Yang BY, Jeong JM, et al. Simultaneous multiparametric PET/MRI with silicon photomultiplier PET and ultra-high-field MRI for small-animal imaging. J Nucl Med 2016;57:1309-1315. https://doi.org/10.2967/jnumed.115.170019
- Jacobson O, Chen X. PET designated flouride-18 production and chemistry. Curr Top Med Chem 2010;10:1048-1059. https://doi.org/10.2174/156802610791384298
- Goulding H, Pinder S, Cannon P, Pearson D, Nicholson R, Snead D, et al. A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples. Hum Pathol 1995;26:291-294. https://doi.org/10.1016/0046-8177(95)90060-8
- Lu P, Yu L, Li Y, Sun Y. A correlation study between maximum standardized uptake values and pathology and clinical staging in nonsmall cell lung cancer. Nucl Med Commun 2010;31:646-651. https://doi.org/10.1097/mnm.0b013e328339bddb
- Khalaf M, Abdel-Nabi H, Baker J, Shao Y, Lamonica D, Gona J. Relation between nodule size and 18F-FDG-PET SUV for malignant and benign pulmonary nodules. J Hematol Oncol 2008;1:13. https://doi.org/10.1186/1756-8722-1-13
- Pleitz JL, Sinha P, Dressler EV, Aouad RK. Correlation of positron emission tomography/computed tomography scan with smoking, tumor size, stage and differentiation in head and neck cancer patients. World J Nucl Med 2017;16:51-55. https://doi.org/10.4103/1450-1147.181156
- Tian J, Chen L, Wei B, Shao M, Ding Y, Yin D, et al. The value of vesicant 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) in gastric malignancies. Nucl Med Commun 2004;25:825-831. https://doi.org/10.1097/01.mnm.0000135042.54461.f6
-
Kim SK, Kang KW, Lee JS, Kim HK, Chang HJ, Choi JY, et al. Assessment of lymph node metastases using
$^{18}F$ -FDG PET in patients with advanced gastric cancer. Eur J Nucl Med Mol Imaging 2006;33:148-155. https://doi.org/10.1007/s00259-005-1887-8 - Kim HW, Won KS, Song BI, Kang YN. Correlation of primary tumor FDG uptake with histopathologic features of advanced gastric cancer. Nucl Med Mol Imaging 2015;49:135-142. https://doi.org/10.1007/s13139-015-0327-3
-
Miao Y, Zhang LF, Guo R, Liang S, Zhang M, Shi S, et al.
$^{18}F$ -FDG PET/CT for monitoring the response of breast cancer to miR-143-based therapeutics by targeting tumor glycolysis. Mol Ther Nucleic Acids 2016;5:e357. https://doi.org/10.1038/mtna.2016.72 -
Fledelius J, Winther-Larsen A, Khalil AA, Bylov CM, Hjorthaug K, Bertelsen A, et al.
$^{18}F$ -FDG PET/CT for very early response evaluation predicts CT response in erlotinib-treated non-small cell lung cancer patients: a comparison of assessment methods. J Nucl Med 2017;58:1931-1937. https://doi.org/10.2967/jnumed.117.193003 -
Valtorta S, Moro M, Prisinzano G, Bertolini G, Tortoreto M, Raccagni I, et al. Metabolic evaluation of non-small cell lung cancer patient-derived xenograft models using
$^{18}F$ -FDG PET: a potential tool for early therapy response. J Nucl Med 2017;58:42-47. https://doi.org/10.2967/jnumed.116.176404 - Haldorsen IS, Popa M, Fonnes T, Brekke N, Kopperud R, Visser NC, et al. Multimodal imaging of orthotopic mouse model of endometrial carcinoma. PLoS One 2015;10:e0135220. https://doi.org/10.1371/journal.pone.0135220
- Partecke IL, Kaeding A, Sendler M, Albers N, Kuhn JP, Speerforck S, et al. In vivo imaging of pancreatic tumours and liver metastases using 7 Tesla MRI in a murine orthotopic pancreatic cancer model and a liver metastases model. BMC Cancer 2011;11:40. https://doi.org/10.1186/1471-2407-11-40
- Ramasawmy R, Johnson SP, Roberts TA, Stuckey DJ, David AL, Pedley RB, et al. Monitoring the growth of an orthotopic tumour xenograft model: multi-modal imaging assessment with benchtop MRI (1T), high-field MRI (9.4T), ultrasound and bioluminescence. PLoS One 2016;11:e0156162. https://doi.org/10.1371/journal.pone.0156162
- Qiu W, Su GH. Development of orthotopic pancreatic tumor mouse models. Methods Mol Biol 2013;980:215-223. https://doi.org/10.1007/978-1-62703-287-2_11